We are honored to participate in the highly anticipated ESHRE 2024 Conference, a global stage where the future of reproductive medicine takes shape. This premier event brings together renowned scientists, clinicians, and innovators to share groundbreaking discoveries, transformative treatments, and state-of-the-art technologies. At this year’s conference, Prolistem is taking center stage with the presentation of […]
We are honored to participate in the prestigious ASRM 2024 Conference in Denver, Colorado, a cornerstone event in the world of reproductive medicine. This gathering unites leading experts, innovators, and pioneers in the field, providing an unparalleled platform for unveiling cutting-edge technologies, groundbreaking treatments, and transformative research that redefine the future of fertility care. At […]
Prolistem® Joins the ASRM 2024 Conference in Denver We are thrilled to announce that Prolistem® will be participating in the highly anticipated American Society for Reproductive Medicine (ASRM) 2024 Conference, held in the vibrant city of Denver, Colorado. The ASRM annual meeting is a premier event in the field of reproductive medicine, bringing together leading […]
The Prolistem treatment has emerged as a breakthrough for men grappling with non-obstructive azoospermia, a condition that can be incredibly challenging to address. Its efficacy and safety have been rigorously assessed and endorsed by the Turkish Urology Association, elevating it to the esteemed status of the gold standard in pre-microTESE care. This approval signifies not […]
He main point of the article “Inhibition of Spermatogonial Differentiation by Testosterone” is that testosterone can inhibit the differentiation of spermatogonia, which are the stem cells of the testis that give rise to sperm. This inhibition can occur in a variety of pathological conditions, such as testicular irradiation, chemotherapy, and cryptorchidism. In these conditions, testosterone […]
We are thrilled to announce that Prolistem®, developed by Medhija LLC, has received approval from the Jordan Food and Drug Administration (JFDA). We are pleased to introduce Robou Yabroud Medical EST. as our official distributor in Jordan For more information and treatment protocols contact Jordan official distributor: ROBOU YABROUD MEDICAL EST. Mohmmad Al Abed Phone: […]
Prolistem, a patented formula, has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Copyright © 2023 Prolistem®
Prolistem, a patented formula, has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Copyright © 2023 Prolistem®
